tetano
Editor, Senior Moderator
Nat Commun
. 2021 Sep 14;12(1):5417.
doi: 10.1038/s41467-021-25509-3.
New-onset IgG autoantibodies in hospitalized patients with COVID-19
Sarah Esther Chang[SUP] #[/SUP][SUP] 1 2 [/SUP], Allan Feng[SUP] #[/SUP][SUP] 1 2 [/SUP], Wenzhao Meng[SUP] #[/SUP][SUP] 3 [/SUP], Sokratis A Apostolidis[SUP] #[/SUP][SUP] 4 5 [/SUP], Elisabeth Mack[SUP] 6 [/SUP], Maja Artandi[SUP] 7 8 [/SUP], Linda Barman[SUP] 7 [/SUP], Kate Bennett[SUP] 9 [/SUP], Saborni Chakraborty[SUP] 10 [/SUP], Iris Chang[SUP] 2 11 [/SUP], Peggie Cheung[SUP] 1 2 [/SUP], Sharon Chinthrajah[SUP] 2 11 [/SUP], Shaurya Dhingra[SUP] 1 2 [/SUP], Evan Do[SUP] 2 11 [/SUP], Amanda Finck[SUP] 12 [/SUP], Andrew Gaano[SUP] 3 [/SUP], Reinhard Geßner[SUP] 13 [/SUP], Heather M Giannini[SUP] 14 [/SUP], Joyce Gonzalez[SUP] 3 [/SUP], Sarah Greib[SUP] 13 [/SUP], Margrit Gündisch[SUP] 13 [/SUP], Alex Ren Hsu[SUP] 1 2 [/SUP], Alex Kuo[SUP] 1 2 [/SUP], Monali Manohar[SUP] 2 10 [/SUP], Rong Mao[SUP] 1 2 [/SUP], Indira Neeli[SUP] 14 [/SUP], Andreas Neubauer[SUP] 6 [/SUP], Oluwatosin Oniyide[SUP] 15 [/SUP], Abigail E Powell[SUP] 16 17 [/SUP], Rajan Puri[SUP] 7 [/SUP], Harald Renz[SUP] 13 18 [/SUP], Jeffrey Schapiro[SUP] 19 [/SUP], Payton A Weidenbacher[SUP] 16 17 [/SUP], Richard Wittman[SUP] 7 [/SUP], Neera Ahuja[SUP] 20 [/SUP], Ho-Ryun Chung[SUP] 21 [/SUP], Prasanna Jagannathan[SUP] 2 10 22 [/SUP], Judith A James[SUP] 23 [/SUP], Peter S Kim[SUP] 14 16 24 [/SUP], Nuala J Meyer[SUP] 5 15 [/SUP], Kari C Nadeau[SUP] 2 11 [/SUP], Marko Radic[SUP] 14 [/SUP], William H Robinson[SUP] 1 2 25 [/SUP], Upinder Singh[SUP] 2 10 22 [/SUP], Taia T Wang[SUP] 10 22 24 [/SUP], E John Wherry[SUP] 5 12 [/SUP], Chrysanthi Skevaki[SUP] 26 27 [/SUP], Eline T Luning Prak[SUP] 28 29 [/SUP], Paul J Utz[SUP] 30 31 [/SUP]
Affiliations
Abstract
COVID-19 is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. Here we develop three protein arrays to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients. Autoantibodies are identified in approximately 50% of patients but in less than 15% of healthy controls. When present, autoantibodies largely target autoantigens associated with rare disorders such as myositis, systemic sclerosis and overlap syndromes. A subset of autoantibodies targeting traditional autoantigens or cytokines develop de novo following SARS-CoV-2 infection. Autoantibodies track with longitudinal development of IgG antibodies recognizing SARS-CoV-2 structural proteins and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.
. 2021 Sep 14;12(1):5417.
doi: 10.1038/s41467-021-25509-3.
New-onset IgG autoantibodies in hospitalized patients with COVID-19
Sarah Esther Chang[SUP] #[/SUP][SUP] 1 2 [/SUP], Allan Feng[SUP] #[/SUP][SUP] 1 2 [/SUP], Wenzhao Meng[SUP] #[/SUP][SUP] 3 [/SUP], Sokratis A Apostolidis[SUP] #[/SUP][SUP] 4 5 [/SUP], Elisabeth Mack[SUP] 6 [/SUP], Maja Artandi[SUP] 7 8 [/SUP], Linda Barman[SUP] 7 [/SUP], Kate Bennett[SUP] 9 [/SUP], Saborni Chakraborty[SUP] 10 [/SUP], Iris Chang[SUP] 2 11 [/SUP], Peggie Cheung[SUP] 1 2 [/SUP], Sharon Chinthrajah[SUP] 2 11 [/SUP], Shaurya Dhingra[SUP] 1 2 [/SUP], Evan Do[SUP] 2 11 [/SUP], Amanda Finck[SUP] 12 [/SUP], Andrew Gaano[SUP] 3 [/SUP], Reinhard Geßner[SUP] 13 [/SUP], Heather M Giannini[SUP] 14 [/SUP], Joyce Gonzalez[SUP] 3 [/SUP], Sarah Greib[SUP] 13 [/SUP], Margrit Gündisch[SUP] 13 [/SUP], Alex Ren Hsu[SUP] 1 2 [/SUP], Alex Kuo[SUP] 1 2 [/SUP], Monali Manohar[SUP] 2 10 [/SUP], Rong Mao[SUP] 1 2 [/SUP], Indira Neeli[SUP] 14 [/SUP], Andreas Neubauer[SUP] 6 [/SUP], Oluwatosin Oniyide[SUP] 15 [/SUP], Abigail E Powell[SUP] 16 17 [/SUP], Rajan Puri[SUP] 7 [/SUP], Harald Renz[SUP] 13 18 [/SUP], Jeffrey Schapiro[SUP] 19 [/SUP], Payton A Weidenbacher[SUP] 16 17 [/SUP], Richard Wittman[SUP] 7 [/SUP], Neera Ahuja[SUP] 20 [/SUP], Ho-Ryun Chung[SUP] 21 [/SUP], Prasanna Jagannathan[SUP] 2 10 22 [/SUP], Judith A James[SUP] 23 [/SUP], Peter S Kim[SUP] 14 16 24 [/SUP], Nuala J Meyer[SUP] 5 15 [/SUP], Kari C Nadeau[SUP] 2 11 [/SUP], Marko Radic[SUP] 14 [/SUP], William H Robinson[SUP] 1 2 25 [/SUP], Upinder Singh[SUP] 2 10 22 [/SUP], Taia T Wang[SUP] 10 22 24 [/SUP], E John Wherry[SUP] 5 12 [/SUP], Chrysanthi Skevaki[SUP] 26 27 [/SUP], Eline T Luning Prak[SUP] 28 29 [/SUP], Paul J Utz[SUP] 30 31 [/SUP]
Affiliations
- PMID: 34521836
- DOI: 10.1038/s41467-021-25509-3
Abstract
COVID-19 is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. Here we develop three protein arrays to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients. Autoantibodies are identified in approximately 50% of patients but in less than 15% of healthy controls. When present, autoantibodies largely target autoantigens associated with rare disorders such as myositis, systemic sclerosis and overlap syndromes. A subset of autoantibodies targeting traditional autoantigens or cytokines develop de novo following SARS-CoV-2 infection. Autoantibodies track with longitudinal development of IgG antibodies recognizing SARS-CoV-2 structural proteins and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.